Hepion Says FDA Feedback Supports GV104 Prophylaxis Modeling
Hepion said FDA written feedback reaffirmed its modeling approach for demonstrating GV104 prophylactic protection and included comments to improve simulations. A submitted analysis predicted complete protection in 200 simulations using a 16 mg buccal film taken at least 15 minutes before exposure.
Story updates
12:08:04 PM UTC
SquawkNews
Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest